Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD

Woo J. Kim, Seung S. Sheen, Tae Hyung Kim, Jin W. Huh, Ji Hyun Lee, Eun Kyung Kim, Jin H. Lee, Sang Min Lee, Sang Yeub Lee, Seong Y. Lim, Tae R. Shin, Ho I. Yoon, Yeon Mok Oh, Sang D. Lee

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background and objective: Inhaled corticosteroids are used to treat COPD and asthma. An association between sequence variants in the corticotrophin- releasing hormone receptor 1 (CRHR1) gene and improved lung function in asthmatics treated with inhaled corticosteroids was reported recently. This study investigated the association between the change in lung function in response to inhaled corticosteroids and single-nucleotide CRHR1 polymorphisms in patients with COPD. Methods: COPD patients (n = 87) with a positive smoking history were recruited from the pulmonary clinics of 11 hospitals in Korea. Patients were treated with fluticasone propionate and salmeterol for 12 weeks and lung function was measured at baseline and after the 12-week treatment. Eighty-four of the 87 subjects were successfully genotyped. Results: Seventy-one patients with the wild-type GG genotype and 13 patients with the heterozygous GT genotype in rs242 941 were evaluated. After 12-week treatment, the change in FEV 1 was significantly higher in patients with wild-type GG genotype (6.0 ± 0.8% of predicted FEV 1) than in GT heterozygotes (-0.8 ± 1.8, P = 0.003). Conclusions: Improved FEV 1 following inhaled corticosteroid and a long-acting β2-agonist was associated with CRHR1 genetic polymorphism in patients with COPD.

Original languageEnglish
Pages (from-to)260-263
Number of pages4
JournalRespirology
Volume14
Issue number2
DOIs
Publication statusPublished - 2009 Mar 1

Fingerprint

Corticotropin-Releasing Hormone Receptors
Chronic Obstructive Pulmonary Disease
Adrenal Cortex Hormones
Lung
Genotype
Genetic Polymorphisms
Heterozygote
Korea
Asthma
Nucleotides
Smoking
History
Therapeutics

Keywords

  • COPD
  • Corticosteroid
  • CRHR1
  • Polymorphism

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. / Kim, Woo J.; Sheen, Seung S.; Kim, Tae Hyung; Huh, Jin W.; Lee, Ji Hyun; Kim, Eun Kyung; Lee, Jin H.; Lee, Sang Min; Lee, Sang Yeub; Lim, Seong Y.; Shin, Tae R.; Yoon, Ho I.; Oh, Yeon Mok; Lee, Sang D.

In: Respirology, Vol. 14, No. 2, 01.03.2009, p. 260-263.

Research output: Contribution to journalArticle

Kim, WJ, Sheen, SS, Kim, TH, Huh, JW, Lee, JH, Kim, EK, Lee, JH, Lee, SM, Lee, SY, Lim, SY, Shin, TR, Yoon, HI, Oh, YM & Lee, SD 2009, 'Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD', Respirology, vol. 14, no. 2, pp. 260-263. https://doi.org/10.1111/j.1440-1843.2008.01425.x
Kim, Woo J. ; Sheen, Seung S. ; Kim, Tae Hyung ; Huh, Jin W. ; Lee, Ji Hyun ; Kim, Eun Kyung ; Lee, Jin H. ; Lee, Sang Min ; Lee, Sang Yeub ; Lim, Seong Y. ; Shin, Tae R. ; Yoon, Ho I. ; Oh, Yeon Mok ; Lee, Sang D. / Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD. In: Respirology. 2009 ; Vol. 14, No. 2. pp. 260-263.
@article{3d25f826eb9b44799ccf083dbaddd52d,
title = "Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD",
abstract = "Background and objective: Inhaled corticosteroids are used to treat COPD and asthma. An association between sequence variants in the corticotrophin- releasing hormone receptor 1 (CRHR1) gene and improved lung function in asthmatics treated with inhaled corticosteroids was reported recently. This study investigated the association between the change in lung function in response to inhaled corticosteroids and single-nucleotide CRHR1 polymorphisms in patients with COPD. Methods: COPD patients (n = 87) with a positive smoking history were recruited from the pulmonary clinics of 11 hospitals in Korea. Patients were treated with fluticasone propionate and salmeterol for 12 weeks and lung function was measured at baseline and after the 12-week treatment. Eighty-four of the 87 subjects were successfully genotyped. Results: Seventy-one patients with the wild-type GG genotype and 13 patients with the heterozygous GT genotype in rs242 941 were evaluated. After 12-week treatment, the change in FEV 1 was significantly higher in patients with wild-type GG genotype (6.0 ± 0.8{\%} of predicted FEV 1) than in GT heterozygotes (-0.8 ± 1.8, P = 0.003). Conclusions: Improved FEV 1 following inhaled corticosteroid and a long-acting β2-agonist was associated with CRHR1 genetic polymorphism in patients with COPD.",
keywords = "COPD, Corticosteroid, CRHR1, Polymorphism",
author = "Kim, {Woo J.} and Sheen, {Seung S.} and Kim, {Tae Hyung} and Huh, {Jin W.} and Lee, {Ji Hyun} and Kim, {Eun Kyung} and Lee, {Jin H.} and Lee, {Sang Min} and Lee, {Sang Yeub} and Lim, {Seong Y.} and Shin, {Tae R.} and Yoon, {Ho I.} and Oh, {Yeon Mok} and Lee, {Sang D.}",
year = "2009",
month = "3",
day = "1",
doi = "10.1111/j.1440-1843.2008.01425.x",
language = "English",
volume = "14",
pages = "260--263",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Association between CRHR1 polymorphism and improved lung function in response to inhaled corticosteroid in patients with COPD

AU - Kim, Woo J.

AU - Sheen, Seung S.

AU - Kim, Tae Hyung

AU - Huh, Jin W.

AU - Lee, Ji Hyun

AU - Kim, Eun Kyung

AU - Lee, Jin H.

AU - Lee, Sang Min

AU - Lee, Sang Yeub

AU - Lim, Seong Y.

AU - Shin, Tae R.

AU - Yoon, Ho I.

AU - Oh, Yeon Mok

AU - Lee, Sang D.

PY - 2009/3/1

Y1 - 2009/3/1

N2 - Background and objective: Inhaled corticosteroids are used to treat COPD and asthma. An association between sequence variants in the corticotrophin- releasing hormone receptor 1 (CRHR1) gene and improved lung function in asthmatics treated with inhaled corticosteroids was reported recently. This study investigated the association between the change in lung function in response to inhaled corticosteroids and single-nucleotide CRHR1 polymorphisms in patients with COPD. Methods: COPD patients (n = 87) with a positive smoking history were recruited from the pulmonary clinics of 11 hospitals in Korea. Patients were treated with fluticasone propionate and salmeterol for 12 weeks and lung function was measured at baseline and after the 12-week treatment. Eighty-four of the 87 subjects were successfully genotyped. Results: Seventy-one patients with the wild-type GG genotype and 13 patients with the heterozygous GT genotype in rs242 941 were evaluated. After 12-week treatment, the change in FEV 1 was significantly higher in patients with wild-type GG genotype (6.0 ± 0.8% of predicted FEV 1) than in GT heterozygotes (-0.8 ± 1.8, P = 0.003). Conclusions: Improved FEV 1 following inhaled corticosteroid and a long-acting β2-agonist was associated with CRHR1 genetic polymorphism in patients with COPD.

AB - Background and objective: Inhaled corticosteroids are used to treat COPD and asthma. An association between sequence variants in the corticotrophin- releasing hormone receptor 1 (CRHR1) gene and improved lung function in asthmatics treated with inhaled corticosteroids was reported recently. This study investigated the association between the change in lung function in response to inhaled corticosteroids and single-nucleotide CRHR1 polymorphisms in patients with COPD. Methods: COPD patients (n = 87) with a positive smoking history were recruited from the pulmonary clinics of 11 hospitals in Korea. Patients were treated with fluticasone propionate and salmeterol for 12 weeks and lung function was measured at baseline and after the 12-week treatment. Eighty-four of the 87 subjects were successfully genotyped. Results: Seventy-one patients with the wild-type GG genotype and 13 patients with the heterozygous GT genotype in rs242 941 were evaluated. After 12-week treatment, the change in FEV 1 was significantly higher in patients with wild-type GG genotype (6.0 ± 0.8% of predicted FEV 1) than in GT heterozygotes (-0.8 ± 1.8, P = 0.003). Conclusions: Improved FEV 1 following inhaled corticosteroid and a long-acting β2-agonist was associated with CRHR1 genetic polymorphism in patients with COPD.

KW - COPD

KW - Corticosteroid

KW - CRHR1

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=61349181840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349181840&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2008.01425.x

DO - 10.1111/j.1440-1843.2008.01425.x

M3 - Article

VL - 14

SP - 260

EP - 263

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 2

ER -